Inhibitors targeting BRAF mutant tumors (3–5% of lung cancers), MET overexpressing tumors (3–4% of ADC cases) and tumors harboring RET fusion proteins (1–2% of NSCLC) are also currently undergoing preclinical and clinical studies (Hirsch et al., 2017). The gene discussed is MET; the disease is AIDS dementia complex.